Michael Rapp Biography and Net Worth

Director of Immunome

Michael Rapp has more than 30 years of experience in the financial industry and is the Managing Member of Broadband Capital Investments, LLC, a middle-market private equity sponsor focused on high growth companies. Mr. Rapp has been instrumental in providing early financing and for advising exciting growth companies including; Examworks (acquired by Leonard Green), Montrose Environmental (the leading US environmental services company), Vroom.com (Nasdaq: VRM), the leading internet used car company, Zynerba Pharmaceuticals (Nasdaq: ZYNE), a leading cannabinoid biotech company, and Hydrofarm (a leading hydroponics distribution company). Mr. Rapp received his BA degree in psychology from the University of Michigan-Ann Arbor in 1989.

What is Michael Rapp's net worth?: The estimated net worth of Michael Rapp is at least $16.07 million as of September 13th, 2021. Mr. Rapp owns 799,866 shares of Immunome stock worth more than $16,069,308 as of December 4th. This net worth estimate does not reflect any other investments that Mr. Rapp may own. Learn More about Michael Rapp's net worth.
How do I contact Michael Rapp?: The corporate mailing address for Mr. Rapp and other Immunome executives is , , . Immunome can also be reached via phone at 610-321-3700 and via email at [email protected]. Learn More on Michael Rapp's contact information.
Has Michael Rapp been buying or selling shares of Immunome?: Michael Rapp has not been actively trading shares of Immunome within the last three months. Most recently, on Monday, September 13th, Michael Rapp bought 25,962 shares of Immunome stock. The stock was acquired at an average cost of $19.96 per share, with a total value of $518,201.52. Following the completion of the transaction, the director now directly owns 799,866 shares of the company's stock, valued at $15,965,325.36. Learn More on Michael Rapp's trading history.
Who are Immunome's active insiders?: Immunome's insider roster includes Jean Bienaime (Director), Jack Higgins (Insider), Robert Lechleider (Insider), Michael Lefenfeld (Director), Michael Rapp (Director), Max Rosett (CFO), Purnanand Sarma (CEO), Clay Siegall (CEO), Philip Tsai (CTO), and Bruce Turner (Insider). Learn More on Immunome's active insiders.
Are insiders buying or selling shares of Immunome?: In the last twelve months, Immunome insiders bought shares 5 times. They purchased a total of 311,400 shares worth more than $2,369,895.00. The most recent insider tranaction occured on June, 3rd when Director Jean Jacques Bienaime bought 5,000 shares worth more than $46,900.00. Insiders at Immunome own 7.7% of the company. Learn More about insider trades at Immunome.
Information on this page was last updated on 6/3/2025.

Michael Rapp Insider Trading History at Immunome

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/13/2021	Buy	25,962	$19.96	$518,201.52	799,866
9/9/2021	Buy	30,450	$18.19	$553,885.50	799,866
10/6/2020	Buy	83,332	$12.00	$999,984.00	555,554

Michael Rapp Buying and Selling Activity at Immunome

Immunome Company Overview

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Today's Range

Now: $20.09

$18.91

$20.40

50 Day Range

MA: $15.98

$11.34

$20.09

2 Week Range

Now: $20.09

$5.15

$20.40

Volume

1,531,875 shs

Average Volume

1,267,980 shs

Market Capitalization

$1.84 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.17